Costing Behavioral Interventions: A Practical Guide to Enhance Translation
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Cost and cost effectiveness of behavioral interventions are critical parts of dissemination and implementation into non-academic settings. Due to the lack of indicative data and policy makers’ increasing demands for both program effectiveness and efficiency, cost analyses can serve as valuable tools in the evaluation process.
To stimulate and promote broader use of practical techniques that can be used to efficiently estimate the implementation costs of behavioral interventions, we propose a set of analytic steps that can be employed across a broad range of interventions.
Intervention costs must be distinguished from research, development, and recruitment costs. The inclusion of sensitivity analyses is recommended to understand the implications of implementation of the intervention into different settings using different intervention resources. To illustrate these procedures, we use data from a smoking reduction practical clinical trial to describe the techniques and methods used to estimate and evaluate the costs associated with the intervention. Estimated intervention costs per participant were $419, with a range of $276 to $703, depending on the number of participants.
- Glasgow RE, Emmons KM. How can we increase translation of research into practice? Annu Rev Pub Health. 2007; 281: 413–433. CrossRef
- Grosse SD, Teutsch SM, Haddix C. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Pub Health. 2007; 28: 365–391. CrossRef
- Hoffmann C, Stoykova BA, Nixon J, et al. Do healthcare decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health. 2002; 52: 71–78. CrossRef
- Reinhardt UE. Making economic evaluations respectable. Soc Sci Med. 1997; 454: 555–562. CrossRef
- Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decision, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med. 1997; 454: 523–533. CrossRef
- Rogers EM. Diffusion of innovations. 5th ed. New York: Free Press; 2003.
- Glasgow RE, Linnan L. Evaluation of theory-based Interventions. In: Glanz K, ed. Health Education: Theory, research and Practice. 4th ed. Hoboken, NJ: Jossey-Bass; 2007.
- Ronckers ST, Groot W, Ament AJ. Systematic review of economic evaluations of smoking cessation: Standardizing the cost-effectiveness. Med Decis Making. 2005; 254: 437–438. CrossRef
- Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR Guideline for Smoking Cessation. JAMA. 1997; 27821: 1759–1766. CrossRef
- Coffield AB, Maciosek Mv, McGinnis JM, et al. Priorities among recommended clinical preventive services. Am J Prev Med. 2001; 211: 1–9. CrossRef
- Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling. JAMA. 1996; 27516: 1247–1251. CrossRef
- Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 2003.
- Hurley SF, Matthews JP. The Quit Benefits Model: A Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Allocation. 2007; 235: 2. CrossRef
- Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: A multinational comparison. Tob Cont. 2006; 153: 152–159. CrossRef
- Tomson T, Helgason AR, Gilljam H. Quitline in smoking cessation: A cost-effectiveness analysis. Int J Technol Assess Health Care. 2004; 204: 469–474. CrossRef
- Lennox AS, Osman LM, Reiter E, et al. Cost effectiveness of computer tailored and non-tailored smoking letters in general practice: Randomised controlled trial. BMJ. 2001; 3227299: 1396. CrossRef
- Buck DJ, Richmond RL, Mendelsohn CP. Cost-effectiveness analysis of a family physician delivered smoking cessation program. Prev Med. 2000; 316: 641–648. CrossRef
- Glasgow RE, Klesges LM, Dzewaltowski DA, et al. The future of health behavior change research: What is needed to improve translation of research into health promotion practice? Ann Behav Med. 2004; 271: 3–12. PMID 14979358. CrossRef
- Centers for Disease Control. The Guide to Community Preventive Services. Available at http://thecommunityguide org. Accessibility verified December 15, 2008.
- Kaplan RM, Groessl EJ. Applications of cost-effectiveness methodologies in behavioral medicine. J Consult Clin Psychol. 2002; 703: 482–493. CrossRef
- Diabetes Prevention Program Research Group. Available at http://diabetes.niddk.nih.gov/dm/pubs/preventionprogram. 2007; Accessibility verified 6/11/08.
- The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003; 26: 36–47. CrossRef
- Meenan RT, Stevens VJ, Hornbrook MC, et al. Cost-effectiveness of a hospital-based smoking-cessation intervention. Med Care. 1998; 365: 670–678. CrossRef
- Ritzwoller DP, Toobert D, Sukhanova A, Glasgow RE. Economic analysis of the Mediterranean Lifestyle Program for Postmenopausal women with diabetes. Diabetes Educ. 2006; 325: 761–769. PMID 16971709. CrossRef
- Koriat A. How do we know that we know? The accessibility model of the feelling of knowing. Psychol Rev. 1993; 1004: 609–639. CrossRef
- Newport DJ, Brennan PA, Green P, et al. Maternal depression and medication exposure during pregnancy: Comparison of maternal recall to prospective documentation. Psychol Rev. 1993; 1004: 609–639. CrossRef
- Bradburn N, Rips L, Shevell S. Answering autobiographic questions: The impacto memory and inference on surveys. Science, New Series. 1987; 2364798: 157–161.
- Levinson AH, Glasgow RE, Gaglio B, et al. Tailored behavioral support for smoking reduction: Development and pilot results of an innovative intervention. Health Educ Res. 2008; 232: 335–346. Apr. CrossRef
- Shiffman S, Gitchell JG, Warner KE, et al. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res. 2002; 4Suppl 2: S113–S129. CrossRef
- Tunis SR, Stryer DB, Clancey CM. Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003; 290: 1624–1632. CrossRef
- Glasgow RE, Magid DJ, Beck A, et al. Practical clinical trials for translating research to practice: Design and measurement recommendations. Med Care. 2005; 436: 551–557. PMID 15908849. CrossRef
- Glasgow RE, Fisher L, Skaff M, et al. Problem-solving and diabetes self-management: Investigation in a large, multi-racial sample. Diabetes Care. 2007; 301: 33–37. CrossRef
- Bureau of Labor Statistics. Available at http://www.bls.gov/bls/blswage.htm. Accessibility verified 11/05/07.
- Keller PA, Bailey LA, Koss KJ, et al. Organization, financing, promotion, and cost of U.S. Quitlines, 2004. Am J Prev Med. 2007; 321: 32–37. CrossRef
- Fishman PA, Thompson E, Merikle E, Curry SJ. Changes in health care costs before and after smoking cessation. Nicotine Tob Res. 2006; 83: 393–401. CrossRef
- Fishman PA, Khan ZM, Thompson EE, Curry SJ. Health care costs among smokers, former smokers, and never smokers in an HMO. Health Serv Res. 2003; 382: 733–749. CrossRef
- Cutler TW, Palmieri J, Khalsa M, Stebbins M. Evaluation of the relationship between a chronic disease care management program and California pay-for-performance diabetes care cholesterol measures in one medical group. J Manage Care Pharm. 2007; 137: 578–588.
- Costing Behavioral Interventions: A Practical Guide to Enhance Translation
Annals of Behavioral Medicine
Volume 37, Issue 2 , pp 218-227
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Cost effectiveness
- Behavioral interventions
- Intervention costs
- Industry Sectors